Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher - Tale of the Tape

Avanir Pharmaceuticals, Inc. AVNR was a big mover last session, as the company saw its shares rise by over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has now gained almost 59% since Apr 28.

This drugs manufacturer has seen one positive and one negative estimate revision over the past 30 days and its Zacks Consensus Estimate has gone down over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Avanir Pharmaceuticals has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.

Some better-ranked stocks in the same industry include Biomerica Inc. (BMRA), Bio-Path Holdings, Inc. (BPTH) and POZEN Inc. POZN. All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

AVANIR PHARM AVNR: Free Stock Analysis Report

BIOMERICA INC (BMRA): Get Free Report

BIO-PATH HLDGS (BPTH): Get Free Report

POZEN INC POZN: Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs